Fulcrum Therapeutics, Inc. (FULC)
Automate Your Wheel Strategy on FULC
With Tiblio's Option Bot, you can configure your own wheel strategy including FULC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FULC
- Rev/Share 0.0
- Book/Share 3.4276
- PB 2.7088
- Debt/Equity 0.0353
- CurrentRatio 24.4155
- ROIC -0.3816
- MktCap 502224167.0
- FreeCF/Share -1.0429
- PFCF -7.6999
- PE -7.9315
- Debt/Assets 0.0331
- DivYield 0
- ROE -0.3105
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | FULC | H.C. Wainwright | Neutral | Buy | $4 | $12 | July 29, 2025 |
| Upgrade | FULC | Leerink Partners | Market Perform | Outperform | -- | $12 | May 23, 2025 |
| Upgrade | FULC | Cantor Fitzgerald | Neutral | Overweight | -- | $10 | May 15, 2025 |
| Downgrade | FULC | H.C. Wainwright | Buy | Neutral | $17 | $4 | Sept. 13, 2024 |
| Downgrade | FULC | RBC Capital Mkts | Outperform | Sector Perform | $15 | $4 | Sept. 12, 2024 |
| Downgrade | FULC | Stifel | Buy | Hold | -- | -- | Sept. 12, 2024 |
| Downgrade | FULC | BofA Securities | Neutral | Underperform | $10 | $2 | Sept. 12, 2024 |
| Downgrade | FULC | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Sept. 12, 2024 |
| Downgrade | FULC | Leerink Partners | Outperform | Market Perform | -- | $4 | Sept. 12, 2024 |
| Upgrade | FULC | BofA Securities | Underperform | Neutral | $5 | $10 | Sept. 9, 2024 |
News
Fulcrum Metal shares jump as tailings project advances
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
Fulcrum Metals Plc (LSE:FMET) shares soared in Wednesday's trade after announcing the start of its Phase Three optimisation work at the Teck-Hughes tailings project in Kirkland Lake, Ontario. The programme with Extrakt Process Solutions aims to refine cyanide-free leaching technology and recovery methods for gold and silver.
Read More
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ―
Read More
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ―
Read More
About Fulcrum Therapeutics, Inc. (FULC)
- IPO Date 2019-07-18
- Website https://www.fulcrumtx.com
- Industry Biotechnology
- CEO Alexander C. Sapir
- Employees 45